Roche has agreed to buy Telavant from Roivant Sciences and Pfizer in a deal worth over $7 billion that will give it rights to a therapy for inflammatory bowel disease and potentially multiple other indications.
Roche has agreed to buy Telavant from Roivant Sciences and Pfizer in a deal worth over $7 billion that will give it rights to a therapy for inflammatory bowel disease and potentially multiple other indications.